TY  - JOUR
AU  - Macut, Đuro
AU  - Mladenović, Violeta
AU  - Bjekić-Macut, Jelica
AU  - Livadas, Sarantis
AU  - Stanojlović, Olivera
AU  - Hrnčić, Dragan
AU  - Rašić-Marković, Aleksandra
AU  - Vojnović-Milutinović, Danijela
AU  - Andrić, Zoran
PY  - 2020
UR  - http://www.eurekaselect.com/172346/article
UR  - http://www.ncbi.nlm.nih.gov/pubmed/31146668
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3969
AB  - Polycystic ovary syndrome (PCOS) is a common endocrine disease in women during reproductive age. It was shown that PCOS women are with high risk for dyslipidemia, glucose intolerance, type 2 diabetes and metabolic syndrome. These factors are considered to represent traditional risk factors for the occurrence of cardiovascular disease. Observed increased risk for hypertension in PCOS women seems to be associated with insulin resistance and hyperinsulinemia. Both conditions interfere with the endothelium-dependent vasodilatation mechanisms causing vascular muscle wall hypertrophy. Obesity and insulin resistance are considered key factors for the alteration of blood pressure in PCOS women. Higher cardiovascular risk is implicated in PCOS with aging and its consequent association with both systolic and diastolic blood pressure. The elements of renin-angiotensin-aldosterone system (RAAS) have an impact on endothelial dysfunction as a marker of cardiovascular damage that could be modified is women with PCOS. Androgens and components of RAAS are involved in the process of atherogenesis in PCOS women. Therefore, it is hypothesized that spironolactone treatment could ameliorate endothelial dysfunction in PCOS women. Recently it was shown that telmisartan, angiotensin II receptor antagonist poses insulinsensitizing capacity to activate PPAR gamma and mediate favorable metabolic and reproductive effects in hypertensive PCOS women.
PB  - Bentham Science Publishers Ltd.
T2  - Current Hypertension Reviews
T1  - Hypertension in Polycystic Ovary Syndrome: Novel Insights.
IS  - 1
VL  - 16
DO  - 10.2174/1573402115666190531071422
SP  - 55
EP  - 60
ER  - 

@article{
author = "Macut, Đuro and Mladenović, Violeta and Bjekić-Macut, Jelica and Livadas, Sarantis and Stanojlović, Olivera and Hrnčić, Dragan and Rašić-Marković, Aleksandra and Vojnović-Milutinović, Danijela and Andrić, Zoran",
year = "2020",
abstract = "Polycystic ovary syndrome (PCOS) is a common endocrine disease in women during reproductive age. It was shown that PCOS women are with high risk for dyslipidemia, glucose intolerance, type 2 diabetes and metabolic syndrome. These factors are considered to represent traditional risk factors for the occurrence of cardiovascular disease. Observed increased risk for hypertension in PCOS women seems to be associated with insulin resistance and hyperinsulinemia. Both conditions interfere with the endothelium-dependent vasodilatation mechanisms causing vascular muscle wall hypertrophy. Obesity and insulin resistance are considered key factors for the alteration of blood pressure in PCOS women. Higher cardiovascular risk is implicated in PCOS with aging and its consequent association with both systolic and diastolic blood pressure. The elements of renin-angiotensin-aldosterone system (RAAS) have an impact on endothelial dysfunction as a marker of cardiovascular damage that could be modified is women with PCOS. Androgens and components of RAAS are involved in the process of atherogenesis in PCOS women. Therefore, it is hypothesized that spironolactone treatment could ameliorate endothelial dysfunction in PCOS women. Recently it was shown that telmisartan, angiotensin II receptor antagonist poses insulinsensitizing capacity to activate PPAR gamma and mediate favorable metabolic and reproductive effects in hypertensive PCOS women.",
publisher = "Bentham Science Publishers Ltd.",
journal = "Current Hypertension Reviews",
title = "Hypertension in Polycystic Ovary Syndrome: Novel Insights.",
number = "1",
volume = "16",
doi = "10.2174/1573402115666190531071422",
pages = "55-60"
}

Macut, Đ., Mladenović, V., Bjekić-Macut, J., Livadas, S., Stanojlović, O., Hrnčić, D., Rašić-Marković, A., Vojnović-Milutinović, D.,& Andrić, Z.. (2020). Hypertension in Polycystic Ovary Syndrome: Novel Insights.. in Current Hypertension Reviews
Bentham Science Publishers Ltd.., 16(1), 55-60.
https://doi.org/10.2174/1573402115666190531071422

Macut Đ, Mladenović V, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, Rašić-Marković A, Vojnović-Milutinović D, Andrić Z. Hypertension in Polycystic Ovary Syndrome: Novel Insights.. in Current Hypertension Reviews. 2020;16(1):55-60.
doi:10.2174/1573402115666190531071422 .

Macut, Đuro, Mladenović, Violeta, Bjekić-Macut, Jelica, Livadas, Sarantis, Stanojlović, Olivera, Hrnčić, Dragan, Rašić-Marković, Aleksandra, Vojnović-Milutinović, Danijela, Andrić, Zoran, "Hypertension in Polycystic Ovary Syndrome: Novel Insights." in Current Hypertension Reviews, 16, no. 1 (2020):55-60,
https://doi.org/10.2174/1573402115666190531071422 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Bjekić-Macut, Jelica
AU  - Livadas, Sarantis
AU  - Stanojlović, Olivera
AU  - Hrnčić, Dragan
AU  - Rašić-Marković, Aleksandra
AU  - Vojnović-Milutinović, Danijela
AU  - Mladenović, Violeta
AU  - Andrić, Zoran
PY  - 2019
UR  - http://www.eurekaselect.com/169068/article
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3308
AB  - Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women during the reproductive period. True PCOS phenotype is prone to develop metabolic consequences during life. Obese PCOS women with insulin resistance are carrying a risk for developing type 2 diabetes, and influencing liver function by generating liver steatosis and nonalcoholic fatty liver disease (NAFLD). Moreover, serum testosterone of over 3 nmol/L is associated with at least two-fold higher risk for the development of NAFLD in PCOS women. Numerous genes involved in the pathogenesis of hyperandrogenism, insulin resistance and inflammation are associated with the development of NAFLD in PCOS women. Liver biopsy is not considered as the first line procedure for the diagnosis of liver damage in a prevalent condition as PCOS. Therefore, simple and reliable surrogate markers as serum aminotransferases levels or surrogate indexes (i.e. fatty liver index and NAFLD-fatty liver score) could be used for the assessment of fatty liver in PCOS women. First line therapeutic approach for NAFLD in PCOS includes a change in lifestyle that implies dietary regiment and physical activity but without well-defined protocols. Second line therapy considers addition of drugs on the established lifestyle change. Metformin remains the drug of choice for reduction of insulin resistance and liver enzymes level. Liraglutide, glucagon-like peptide-1 receptor agonists, showed favorable effects on the reduction of liver fat content and visceral adipose tissue in overweight women with PCOS. Current review analyzes the impact of metabolic risk factors, diagnostic approach and management options on NAFLD in women with PCOS.
T2  - Current Pharmaceutical Design
T1  - Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome
IS  - 38
VL  - 24
DO  - 10.2174/1381612825666190117100751
SP  - 4593
EP  - 4597
ER  - 

@article{
author = "Macut, Đuro and Bjekić-Macut, Jelica and Livadas, Sarantis and Stanojlović, Olivera and Hrnčić, Dragan and Rašić-Marković, Aleksandra and Vojnović-Milutinović, Danijela and Mladenović, Violeta and Andrić, Zoran",
year = "2019",
abstract = "Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women during the reproductive period. True PCOS phenotype is prone to develop metabolic consequences during life. Obese PCOS women with insulin resistance are carrying a risk for developing type 2 diabetes, and influencing liver function by generating liver steatosis and nonalcoholic fatty liver disease (NAFLD). Moreover, serum testosterone of over 3 nmol/L is associated with at least two-fold higher risk for the development of NAFLD in PCOS women. Numerous genes involved in the pathogenesis of hyperandrogenism, insulin resistance and inflammation are associated with the development of NAFLD in PCOS women. Liver biopsy is not considered as the first line procedure for the diagnosis of liver damage in a prevalent condition as PCOS. Therefore, simple and reliable surrogate markers as serum aminotransferases levels or surrogate indexes (i.e. fatty liver index and NAFLD-fatty liver score) could be used for the assessment of fatty liver in PCOS women. First line therapeutic approach for NAFLD in PCOS includes a change in lifestyle that implies dietary regiment and physical activity but without well-defined protocols. Second line therapy considers addition of drugs on the established lifestyle change. Metformin remains the drug of choice for reduction of insulin resistance and liver enzymes level. Liraglutide, glucagon-like peptide-1 receptor agonists, showed favorable effects on the reduction of liver fat content and visceral adipose tissue in overweight women with PCOS. Current review analyzes the impact of metabolic risk factors, diagnostic approach and management options on NAFLD in women with PCOS.",
journal = "Current Pharmaceutical Design",
title = "Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome",
number = "38",
volume = "24",
doi = "10.2174/1381612825666190117100751",
pages = "4593-4597"
}

Macut, Đ., Bjekić-Macut, J., Livadas, S., Stanojlović, O., Hrnčić, D., Rašić-Marković, A., Vojnović-Milutinović, D., Mladenović, V.,& Andrić, Z.. (2019). Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. in Current Pharmaceutical Design, 24(38), 4593-4597.
https://doi.org/10.2174/1381612825666190117100751

Macut Đ, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, Rašić-Marković A, Vojnović-Milutinović D, Mladenović V, Andrić Z. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. in Current Pharmaceutical Design. 2019;24(38):4593-4597.
doi:10.2174/1381612825666190117100751 .

Macut, Đuro, Bjekić-Macut, Jelica, Livadas, Sarantis, Stanojlović, Olivera, Hrnčić, Dragan, Rašić-Marković, Aleksandra, Vojnović-Milutinović, Danijela, Mladenović, Violeta, Andrić, Zoran, "Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome" in Current Pharmaceutical Design, 24, no. 38 (2019):4593-4597,
https://doi.org/10.2174/1381612825666190117100751 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Vojnović-Milutinović, Danijela
AU  - Rašić-Marković, Aleksandra
AU  - Brkljačić, Jelena
AU  - Bjekić-Macut, Jelica
AU  - Stanojlović, Olivera
PY  - 2018
UR  - http://link.springer.com/10.1007/s42000-018-0073-x
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3220
AB  - Over the last decade, huge achievements have been made in the fields of neurophysiology, molecular endocrinology, and biochemistry, as well as in the successful translation of clinical research into diseases into clinical practice. As regards female reproduction, most of the advances made in this area were achieved in gonadal axis regulation, regulation of behavior through sex steroids, reproductive genetics, preservation of ovarian reproductive function, steroid profiling, and metabolic and overall reproductive outcomes. The coming years are expected to bring further understanding of the relationships between nutrition, energy metabolism, and reproductive function and to succeed in identifying new genetic markers linked to adverse metabolic and unfavorable cardiovascular outcomes in women. From our perspective, future research in the field of female reproduction should be directed toward doing research into genetic reproductive abnormalities and neuroendocrine diseases, pathophysiology, long-term health outcomes for oligo/amenorrhea, hyperandrogenism, and ovulatory dysfunction. It is additionally expected that a better understanding will be gained of the endocrinology of the placenta and of pregnancy, the role of the microbiome in female reproduction, the role of insulin sensitizers, anti-obesity and anti-diabetic drugs, and various advances in the prevention of ovarian damage caused by various oncology therapies, while new therapeutic options for the treatment of infertility, including kisspeptin, will be developed.
T2  - Hormones (Athens, Greece)
T1  - A decade in female reproduction: an endocrine view of the past and into the future.
IS  - 4
VL  - 17
DO  - 10.1007/s42000-018-0073-x
SP  - 497
EP  - 505
ER  - 

@article{
author = "Macut, Đuro and Vojnović-Milutinović, Danijela and Rašić-Marković, Aleksandra and Brkljačić, Jelena and Bjekić-Macut, Jelica and Stanojlović, Olivera",
year = "2018",
abstract = "Over the last decade, huge achievements have been made in the fields of neurophysiology, molecular endocrinology, and biochemistry, as well as in the successful translation of clinical research into diseases into clinical practice. As regards female reproduction, most of the advances made in this area were achieved in gonadal axis regulation, regulation of behavior through sex steroids, reproductive genetics, preservation of ovarian reproductive function, steroid profiling, and metabolic and overall reproductive outcomes. The coming years are expected to bring further understanding of the relationships between nutrition, energy metabolism, and reproductive function and to succeed in identifying new genetic markers linked to adverse metabolic and unfavorable cardiovascular outcomes in women. From our perspective, future research in the field of female reproduction should be directed toward doing research into genetic reproductive abnormalities and neuroendocrine diseases, pathophysiology, long-term health outcomes for oligo/amenorrhea, hyperandrogenism, and ovulatory dysfunction. It is additionally expected that a better understanding will be gained of the endocrinology of the placenta and of pregnancy, the role of the microbiome in female reproduction, the role of insulin sensitizers, anti-obesity and anti-diabetic drugs, and various advances in the prevention of ovarian damage caused by various oncology therapies, while new therapeutic options for the treatment of infertility, including kisspeptin, will be developed.",
journal = "Hormones (Athens, Greece)",
title = "A decade in female reproduction: an endocrine view of the past and into the future.",
number = "4",
volume = "17",
doi = "10.1007/s42000-018-0073-x",
pages = "497-505"
}

Macut, Đ., Vojnović-Milutinović, D., Rašić-Marković, A., Brkljačić, J., Bjekić-Macut, J.,& Stanojlović, O.. (2018). A decade in female reproduction: an endocrine view of the past and into the future.. in Hormones (Athens, Greece), 17(4), 497-505.
https://doi.org/10.1007/s42000-018-0073-x

Macut Đ, Vojnović-Milutinović D, Rašić-Marković A, Brkljačić J, Bjekić-Macut J, Stanojlović O. A decade in female reproduction: an endocrine view of the past and into the future.. in Hormones (Athens, Greece). 2018;17(4):497-505.
doi:10.1007/s42000-018-0073-x .

Macut, Đuro, Vojnović-Milutinović, Danijela, Rašić-Marković, Aleksandra, Brkljačić, Jelena, Bjekić-Macut, Jelica, Stanojlović, Olivera, "A decade in female reproduction: an endocrine view of the past and into the future." in Hormones (Athens, Greece), 17, no. 4 (2018):497-505,
https://doi.org/10.1007/s42000-018-0073-x . .

TY  - JOUR
AU  - Macut, Djuro
AU  - Božić Antić, Ivana
AU  - Bjekić-Macut, Jelica
AU  - Panidis, Dimitrios
AU  - Tziomalos, Konstantinos
AU  - Vojnović Milutinović, Danijela
AU  - Stanojlović, Olivera
AU  - Kastratović-Kotlica, Biljana
AU  - Petakov, Milan
AU  - Milić, Nataša
PY  - 2016
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6332
AB  - OBJECTIVE: There is a need for a simple and accurate method for the assessment of cardiovascular risk in polycystic ovary syndrome (PCOS). Lipid accumulation product (LAP) is based on the assessment of waist circumference and serum triglycerides that yield an estimation of lipid overaccumulation. We aimed to determine whether LAP is associated with metabolic syndrome (MetS) in Caucasian women with PCOS. DESIGN: We studied 222 women with PCOS who were diagnosed using the Rotterdam criteria. In all the subjects and controls, LAP was determined and the MetS was assessed using three different international criteria, NCEP-ATP III, IDF, and JIS. ROC curve and logistic regression analyses were performed to determine and analyze associations with the MetS. RESULTS: In the study population the prevalence of MetS was 16.2–19.4%. The cut-off value of 25.9 determined that LAP has the strongest association with MetS whichever international criteria are used, followed by HDL (NCEP-ATP III and JIS) and glucose (IDF). CONCLUSIONS: LAP is used as an independent clinical indicator for MetS in our PCOS women of Caucasian origin. The high diagnostic accuracy of LAP is superseding the need for the use of multiple clinical indicators for the assessment of lipid accumulation as a prerequisite for diagnosis of metabolic and cardiovascular diseases in PCOS women.
PB  - Springer Nature
T2  - Hormones
T1  - Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome
VL  - 15
DO  - 10.1007/BF03401401
SP  - 35
EP  - 44
ER  - 

@article{
author = "Macut, Djuro and Božić Antić, Ivana and Bjekić-Macut, Jelica and Panidis, Dimitrios and Tziomalos, Konstantinos and Vojnović Milutinović, Danijela and Stanojlović, Olivera and Kastratović-Kotlica, Biljana and Petakov, Milan and Milić, Nataša",
year = "2016",
abstract = "OBJECTIVE: There is a need for a simple and accurate method for the assessment of cardiovascular risk in polycystic ovary syndrome (PCOS). Lipid accumulation product (LAP) is based on the assessment of waist circumference and serum triglycerides that yield an estimation of lipid overaccumulation. We aimed to determine whether LAP is associated with metabolic syndrome (MetS) in Caucasian women with PCOS. DESIGN: We studied 222 women with PCOS who were diagnosed using the Rotterdam criteria. In all the subjects and controls, LAP was determined and the MetS was assessed using three different international criteria, NCEP-ATP III, IDF, and JIS. ROC curve and logistic regression analyses were performed to determine and analyze associations with the MetS. RESULTS: In the study population the prevalence of MetS was 16.2–19.4%. The cut-off value of 25.9 determined that LAP has the strongest association with MetS whichever international criteria are used, followed by HDL (NCEP-ATP III and JIS) and glucose (IDF). CONCLUSIONS: LAP is used as an independent clinical indicator for MetS in our PCOS women of Caucasian origin. The high diagnostic accuracy of LAP is superseding the need for the use of multiple clinical indicators for the assessment of lipid accumulation as a prerequisite for diagnosis of metabolic and cardiovascular diseases in PCOS women.",
publisher = "Springer Nature",
journal = "Hormones",
title = "Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome",
volume = "15",
doi = "10.1007/BF03401401",
pages = "35-44"
}

Macut, D., Božić Antić, I., Bjekić-Macut, J., Panidis, D., Tziomalos, K., Vojnović Milutinović, D., Stanojlović, O., Kastratović-Kotlica, B., Petakov, M.,& Milić, N.. (2016). Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. in Hormones
Springer Nature., 15, 35-44.
https://doi.org/10.1007/BF03401401

Macut D, Božić Antić I, Bjekić-Macut J, Panidis D, Tziomalos K, Vojnović Milutinović D, Stanojlović O, Kastratović-Kotlica B, Petakov M, Milić N. Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. in Hormones. 2016;15:35-44.
doi:10.1007/BF03401401 .

Macut, Djuro, Božić Antić, Ivana, Bjekić-Macut, Jelica, Panidis, Dimitrios, Tziomalos, Konstantinos, Vojnović Milutinović, Danijela, Stanojlović, Olivera, Kastratović-Kotlica, Biljana, Petakov, Milan, Milić, Nataša, "Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome" in Hormones, 15 (2016):35-44,
https://doi.org/10.1007/BF03401401 . .

TY  - JOUR
AU  - Bjekić-Macut, Jelica
AU  - Radosavljević, Vojislav
AU  - Andrić, Zoran
AU  - Ilić, Dušan
AU  - Stanojlović, Olivera
AU  - Vojnović-Milutinović, Danijela
AU  - Božić Antić, Ivana
AU  - Zdravković, Marija
AU  - Hinić, Saša
AU  - Macut, Đuro
AU  - Žarković, Miloš
PY  - 2016
UR  - http://www.degruyter.com/view/j/jomb.2016.35.issue-4/jomb-2016-0015/jomb-2016-0015.xml
UR  - https://www.scopus.com/record/display.uri?eid=2-s2.0-84994910742&origin=SingleRecordEmailAlert&txGid=6CE299281CDB840158BFAC52EC5A2E1C.wsnAw8kcdt7IPYLO0V48gA:63#
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2522
AB  - Background: Systemic inflammatory response syndrome (SIRS) changes cortisol dynamics and indicates dissociation between the adrenal cortex and the hypothalamo-pituitary unit. The aim of this study was to assess the cortisol response after stimulation with ACTH(1-24) in patients with SIRS at admission to the Respiratory Intensive Care Unit (RICU),and seven days later.

Methods: Fifty-four subjects were included in the study, and SIRS was defined according to the Consensus Conference criteria from 1992. Severity of the disease was determined using the APACHE II score, and organ dysfunction using the SOFA score. Low-dose (1 mu g) ACTH test (LDT) was performed in all patients, and cortisol was determined along with basal ACTH. Data were analyzed using parametric and nonparametric tests and regression analysis. The results are presented as mean +/- standard deviation, and P<0.05 was considered statistically significant.

Results: There were no differences in cortisol values between the two LDTs. Cortisol increment lower than 250 nmol/L during the LDT was found in 14/54 (25.9%) subjects at the onset of SIRS. Five out of 54 (9.6%) patients died within 7 days from the onset of SIRS. Female sex and maximal cortisol response (Delta max) on LDT predicted the duration of hospitalization in RICU, while APACHE II and SOFA scores best predicted the duration of hospitalization, mortality outcome as well as overall survival outcome.

Conclusions: A difference was found in Delta max at the diagnosis of SIRS and seven days later. Delta max, and primarily the clinical scores APACHE II and SOFA predicted the outcomes of hospitalization and overall survival.
T2  - Journal of Medical Biochemistry
T1  - Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome
IS  - 4
VL  - 35
DO  - 10.1515/jomb-2016-0015
SP  - 428
EP  - 435
ER  - 

@article{
author = "Bjekić-Macut, Jelica and Radosavljević, Vojislav and Andrić, Zoran and Ilić, Dušan and Stanojlović, Olivera and Vojnović-Milutinović, Danijela and Božić Antić, Ivana and Zdravković, Marija and Hinić, Saša and Macut, Đuro and Žarković, Miloš",
year = "2016",
abstract = "Background: Systemic inflammatory response syndrome (SIRS) changes cortisol dynamics and indicates dissociation between the adrenal cortex and the hypothalamo-pituitary unit. The aim of this study was to assess the cortisol response after stimulation with ACTH(1-24) in patients with SIRS at admission to the Respiratory Intensive Care Unit (RICU),and seven days later.

Methods: Fifty-four subjects were included in the study, and SIRS was defined according to the Consensus Conference criteria from 1992. Severity of the disease was determined using the APACHE II score, and organ dysfunction using the SOFA score. Low-dose (1 mu g) ACTH test (LDT) was performed in all patients, and cortisol was determined along with basal ACTH. Data were analyzed using parametric and nonparametric tests and regression analysis. The results are presented as mean +/- standard deviation, and P<0.05 was considered statistically significant.

Results: There were no differences in cortisol values between the two LDTs. Cortisol increment lower than 250 nmol/L during the LDT was found in 14/54 (25.9%) subjects at the onset of SIRS. Five out of 54 (9.6%) patients died within 7 days from the onset of SIRS. Female sex and maximal cortisol response (Delta max) on LDT predicted the duration of hospitalization in RICU, while APACHE II and SOFA scores best predicted the duration of hospitalization, mortality outcome as well as overall survival outcome.

Conclusions: A difference was found in Delta max at the diagnosis of SIRS and seven days later. Delta max, and primarily the clinical scores APACHE II and SOFA predicted the outcomes of hospitalization and overall survival.",
journal = "Journal of Medical Biochemistry",
title = "Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome",
number = "4",
volume = "35",
doi = "10.1515/jomb-2016-0015",
pages = "428-435"
}

Bjekić-Macut, J., Radosavljević, V., Andrić, Z., Ilić, D., Stanojlović, O., Vojnović-Milutinović, D., Božić Antić, I., Zdravković, M., Hinić, S., Macut, Đ.,& Žarković, M.. (2016). Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome. in Journal of Medical Biochemistry, 35(4), 428-435.
https://doi.org/10.1515/jomb-2016-0015

Bjekić-Macut J, Radosavljević V, Andrić Z, Ilić D, Stanojlović O, Vojnović-Milutinović D, Božić Antić I, Zdravković M, Hinić S, Macut Đ, Žarković M. Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome. in Journal of Medical Biochemistry. 2016;35(4):428-435.
doi:10.1515/jomb-2016-0015 .

Bjekić-Macut, Jelica, Radosavljević, Vojislav, Andrić, Zoran, Ilić, Dušan, Stanojlović, Olivera, Vojnović-Milutinović, Danijela, Božić Antić, Ivana, Zdravković, Marija, Hinić, Saša, Macut, Đuro, Žarković, Miloš, "Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome" in Journal of Medical Biochemistry, 35, no. 4 (2016):428-435,
https://doi.org/10.1515/jomb-2016-0015 . .

TY  - JOUR
AU  - Božić-Antić, Ivana
AU  - Ilić, Dušan
AU  - Bjekić-Macut, Jelica
AU  - Bogavac, Tamara
AU  - Vojnović-Milutinović, Danijela
AU  - Kastratovic-Kotlica, Biljana
AU  - Milić, Nataša
AU  - Stanojlović, Olivera
AU  - Andrić, Zoran
AU  - Macut, Djuro
PY  - 2016
UR  - http://www.eje-online.org/lookup/doi/10.1530/EJE-16-0775
UR  - https://www.scopus.com/record/display.uri?eid=2-s2.0-85000384361&origin=SingleRecordEmailAlert&dgcid=scalert_sc_search_email&txGid=691E27A4B52E4CB98111082A19AFDEEC.wsnAw8kcdt7IPYLO0V48gA%3A9#
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2482
AB  - Objective: There are limited data on cardiometabolic risk factors and the prevalence of metabolic syndrome (MetS) across the different PCOS phenotypes in Caucasian population. Lipid accumulation product (LAP) is a clinical surrogate marker that could be used for evaluation of MetS in clinical practice. The aim of the study was to analyze metabolic characteristics and the ability of LAP to predict MetS in different PCOS phenotypes. Design: Cross-sectional clinical study analyzing 365 women with PCOS divided into four phenotypes according to the ESHRE/ASRM criteria, and 125 healthy BMI-matched controls. Methods: In all subjects, LAP was determined and MetS was diagnosed according to the National Cholesterol Education Program/Adult Treatment Panel III (NCEP-ATP III), the International Diabetes Federation (IDF) and the Joint Interim Statement (JIS) criteria. Logistic regression and ROC curve analyses were used to determine predictors of MetS in each PCOS phenotype. All analyses were performed with age and BMI adjustment. Results: All PCOS phenotypes in comparison to controls had higher prevalence of MetS assessed by NCEP-ATP III criteria, and only classic phenotypes when IDF and JIS criteria were used. All phenotypes had the same prevalence of MetS irrespective of used definition. LAP and exhibited the highest diagnostic accuracy and was an independent predictor of MetS in all phenotypes. Conclusion: LAP is an independent and accurate clinical determinant of MetS in all PCOS phenotypes in our Caucasian population. All PCOS phenotypes, including non-classic ones, are metabolically challenged and with cardiovascular risk, particularly phenotype B.
T2  - European Journal of Endocrinology
T1  - Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome
IS  - 6
VL  - 175
DO  - 10.1530/EJE-16-0775
SP  - 551
EP  - 560
ER  - 

@article{
author = "Božić-Antić, Ivana and Ilić, Dušan and Bjekić-Macut, Jelica and Bogavac, Tamara and Vojnović-Milutinović, Danijela and Kastratovic-Kotlica, Biljana and Milić, Nataša and Stanojlović, Olivera and Andrić, Zoran and Macut, Djuro",
year = "2016",
abstract = "Objective: There are limited data on cardiometabolic risk factors and the prevalence of metabolic syndrome (MetS) across the different PCOS phenotypes in Caucasian population. Lipid accumulation product (LAP) is a clinical surrogate marker that could be used for evaluation of MetS in clinical practice. The aim of the study was to analyze metabolic characteristics and the ability of LAP to predict MetS in different PCOS phenotypes. Design: Cross-sectional clinical study analyzing 365 women with PCOS divided into four phenotypes according to the ESHRE/ASRM criteria, and 125 healthy BMI-matched controls. Methods: In all subjects, LAP was determined and MetS was diagnosed according to the National Cholesterol Education Program/Adult Treatment Panel III (NCEP-ATP III), the International Diabetes Federation (IDF) and the Joint Interim Statement (JIS) criteria. Logistic regression and ROC curve analyses were used to determine predictors of MetS in each PCOS phenotype. All analyses were performed with age and BMI adjustment. Results: All PCOS phenotypes in comparison to controls had higher prevalence of MetS assessed by NCEP-ATP III criteria, and only classic phenotypes when IDF and JIS criteria were used. All phenotypes had the same prevalence of MetS irrespective of used definition. LAP and exhibited the highest diagnostic accuracy and was an independent predictor of MetS in all phenotypes. Conclusion: LAP is an independent and accurate clinical determinant of MetS in all PCOS phenotypes in our Caucasian population. All PCOS phenotypes, including non-classic ones, are metabolically challenged and with cardiovascular risk, particularly phenotype B.",
journal = "European Journal of Endocrinology",
title = "Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome",
number = "6",
volume = "175",
doi = "10.1530/EJE-16-0775",
pages = "551-560"
}

Božić-Antić, I., Ilić, D., Bjekić-Macut, J., Bogavac, T., Vojnović-Milutinović, D., Kastratovic-Kotlica, B., Milić, N., Stanojlović, O., Andrić, Z.,& Macut, D.. (2016). Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome. in European Journal of Endocrinology, 175(6), 551-560.
https://doi.org/10.1530/EJE-16-0775

Božić-Antić I, Ilić D, Bjekić-Macut J, Bogavac T, Vojnović-Milutinović D, Kastratovic-Kotlica B, Milić N, Stanojlović O, Andrić Z, Macut D. Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome. in European Journal of Endocrinology. 2016;175(6):551-560.
doi:10.1530/EJE-16-0775 .

Božić-Antić, Ivana, Ilić, Dušan, Bjekić-Macut, Jelica, Bogavac, Tamara, Vojnović-Milutinović, Danijela, Kastratovic-Kotlica, Biljana, Milić, Nataša, Stanojlović, Olivera, Andrić, Zoran, Macut, Djuro, "Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome" in European Journal of Endocrinology, 175, no. 6 (2016):551-560,
https://doi.org/10.1530/EJE-16-0775 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Bačević, Marina
AU  - Božić-Antić, Ivana
AU  - Bjekić-Macut, Jelica
AU  - Civcic, Milorad
AU  - Erceg, Snježana
AU  - Vojnović-Milutinović, Danijela
AU  - Stanojlović, Olivera
AU  - Andrić, Zoran
AU  - Kastratović-Kotlica, Biljana
AU  - Sukilović, Tijana
PY  - 2015
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2071
AB  - Background. Women with polycystic ovary syndrome (PCOS) could develop
   subclinical atherosclerosis during life. Purpose. To analyze
   cardiovascular risk (CVR) factors and their relation to clinical markers
   of cardiovascular disease (CVD) in respect to their age. Material and
   Methods. One hundred women with PCOS (26.32 +/- 5.26 years, BMI: 24.98
   +/- 6.38 kg/m(2)) were compared to 50 respective controls. In all
   subjects, total cholesterol (TC), HDL-C, LDL-C, triglycerides, TC/HDL-C
   and TG/HDL-C ratios, glucose, insulin and HOMA index, waist-to-hip ratio
   (WHR), systolic and diastolic blood pressure (SBP and DBP, resp.), and
   carotid intima-media thickness (CIMT) were analyzed in respect to their
   age and level of androgens. Results. PCOS over 30 years had higher WHR
   (P = 0.008), SBP (P < 0.001), DBP (P < 0.001), TC (P = 0.028), HDL-C (P
   = 0.028), LDL-C (P = 0.045), triglycerides (P < 0.001), TC/HDL-C (P <
   0.001), and triglycerides/HDL-C (P < 0.001) and had more prevalent
   hypertension and pronounced CIMT on common carotid arteries even after
   adjustment for BMI (P = 0.005 and 0.036, resp.). TC/ HDL-C and TG/HDL-C
   were higher in PCOS with the highest quintile of FAI in comparison to
   those with lower FAI (P = 0.045 and 0.034, resp.). Conclusions. PCOS
   women older than 30 years irrespective of BMI have the potential for
   early atherosclerosismirrored through the elevated lipids/lipid ratios
   and through changes in blood pressure.
T2  - International Journal of Endocrinology
T1  - Predictors of Subclinical Cardiovascular Disease in Women with
 Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and
 Arterial Blood Pressure
IS  - 812610
DO  - 10.1155/2015/812610
ER  - 

@article{
author = "Macut, Đuro and Bačević, Marina and Božić-Antić, Ivana and Bjekić-Macut, Jelica and Civcic, Milorad and Erceg, Snježana and Vojnović-Milutinović, Danijela and Stanojlović, Olivera and Andrić, Zoran and Kastratović-Kotlica, Biljana and Sukilović, Tijana",
year = "2015",
abstract = "Background. Women with polycystic ovary syndrome (PCOS) could develop
   subclinical atherosclerosis during life. Purpose. To analyze
   cardiovascular risk (CVR) factors and their relation to clinical markers
   of cardiovascular disease (CVD) in respect to their age. Material and
   Methods. One hundred women with PCOS (26.32 +/- 5.26 years, BMI: 24.98
   +/- 6.38 kg/m(2)) were compared to 50 respective controls. In all
   subjects, total cholesterol (TC), HDL-C, LDL-C, triglycerides, TC/HDL-C
   and TG/HDL-C ratios, glucose, insulin and HOMA index, waist-to-hip ratio
   (WHR), systolic and diastolic blood pressure (SBP and DBP, resp.), and
   carotid intima-media thickness (CIMT) were analyzed in respect to their
   age and level of androgens. Results. PCOS over 30 years had higher WHR
   (P = 0.008), SBP (P < 0.001), DBP (P < 0.001), TC (P = 0.028), HDL-C (P
   = 0.028), LDL-C (P = 0.045), triglycerides (P < 0.001), TC/HDL-C (P <
   0.001), and triglycerides/HDL-C (P < 0.001) and had more prevalent
   hypertension and pronounced CIMT on common carotid arteries even after
   adjustment for BMI (P = 0.005 and 0.036, resp.). TC/ HDL-C and TG/HDL-C
   were higher in PCOS with the highest quintile of FAI in comparison to
   those with lower FAI (P = 0.045 and 0.034, resp.). Conclusions. PCOS
   women older than 30 years irrespective of BMI have the potential for
   early atherosclerosismirrored through the elevated lipids/lipid ratios
   and through changes in blood pressure.",
journal = "International Journal of Endocrinology",
title = "Predictors of Subclinical Cardiovascular Disease in Women with
 Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and
 Arterial Blood Pressure",
number = "812610",
doi = "10.1155/2015/812610"
}

Macut, Đ., Bačević, M., Božić-Antić, I., Bjekić-Macut, J., Civcic, M., Erceg, S., Vojnović-Milutinović, D., Stanojlović, O., Andrić, Z., Kastratović-Kotlica, B.,& Sukilović, T.. (2015). Predictors of Subclinical Cardiovascular Disease in Women with
 Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and
 Arterial Blood Pressure. in International Journal of Endocrinology(812610).
https://doi.org/10.1155/2015/812610

Macut Đ, Bačević M, Božić-Antić I, Bjekić-Macut J, Civcic M, Erceg S, Vojnović-Milutinović D, Stanojlović O, Andrić Z, Kastratović-Kotlica B, Sukilović T. Predictors of Subclinical Cardiovascular Disease in Women with
 Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and
 Arterial Blood Pressure. in International Journal of Endocrinology. 2015;(812610).
doi:10.1155/2015/812610 .

Macut, Đuro, Bačević, Marina, Božić-Antić, Ivana, Bjekić-Macut, Jelica, Civcic, Milorad, Erceg, Snježana, Vojnović-Milutinović, Danijela, Stanojlović, Olivera, Andrić, Zoran, Kastratović-Kotlica, Biljana, Sukilović, Tijana, "Predictors of Subclinical Cardiovascular Disease in Women with
 Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and
 Arterial Blood Pressure" in International Journal of Endocrinology, no. 812610 (2015),
https://doi.org/10.1155/2015/812610 . .